search
Back to results

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

Primary Purpose

HER2-positive Breast Cancer, Male Breast Cancer, Stage IIIB Breast Cancer

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
HER-2/neu intracellular domain protein
leukapheresis
laboratory biomarker analysis
sargramostim
immunologic technique
synthetic tumor-associated peptide vaccine therapy
Sponsored by
University of Washington
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for HER2-positive Breast Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Stage IIIB or Stage IIIC breast cancer who are within 1 year of diagnosis and initiating treatment with chemotherapy and trastuzumab; and are in complete remission Stage IV breast cancer in first complete remission and defined as NED (no evidence of disease) or with stable bone only disease who are within 6 months of initiating maintenance trastuzumab NED status should be documented by chest/abdominal CT, PET or PET/CT within the last 90 days Bone only disease documented as stable or healed by PET, PET/CT, or MRI within the last 90 days; stable bone-only disease must be documented with bone scan performed within the last 6 months HER2 overexpression by IHC of 2+ or 3+, in the primary tumor or metastasis or documented gene amplification by FISH analysis; if overexpression is 2+ by IHC, then patients must have HER2 gene amplification documented by FISH Eligible subjects must have been treated to NED or stable bone only disease status with trastuzumab and/or chemotherapy and be off cytotoxic chemotherapy or immunosuppressive agents (e.g. systemic steroids) for at least 30 days prior to enrollment (concurrent hormonal therapy allowed; concurrent bisphosphonate therapy allowed) Patients on trastuzumab should continue trastuzumab monotherapy per standard of care (the dosing and schedule of trastuzumab should follow standard guidelines as described below: trastuzumab 2mg/kg IV weekly or trastuzumab 6mg/kg IV every 3 weeks) Subjects must have an ECOG Performance Status Score =< 1 Non-menopausal female subjects must agree to contraception for the remainder of their childbearing years Male subjects must use an acceptable form of contraception throughout the course of the study Hematocrit >= 30,000 Platelet count >= 100,000 WBC >= 3000/mcl Stable creatinine =< 2.0 mg/dl or a creatinine clearance greater than 60 ml/min Serum bilirubin < 1.5 mg/dl SGOT < 2x ULN Laboratory tests should be performed within 60 days of enrollment Subjects must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment Patients on trastuzumab monotherapy must have adequate cardiac function as demonstrated by normal ejection fraction (EF) on MUGA scan or echocardiogram performed within last 6 months Exclusion Criteria: Subjects cannot be simultaneously enrolled in other treatment studies Patients cannot be receiving any other concurrent immunomodulators besides trastuzumab Any contraindication to receiving GM-CSF based vaccine products Cardiac disease, specifically restrictive cardiomyopathy, unstable angina within the last 6 months prior to enrollment, New York Heart Association functional class III-IV heart failure on active treatment with normalized LVEF on therapy, and symptomatic pericardial effusion Active autoimmune disease Subjects can not have active immunodeficiency disorder, e.g. HIV Cannot be pregnant or breast feeding

Sites / Locations

  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Arm I

Arm Description

Patients receive HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF intradermally once monthly for 6 months in the absence of disease progression or unacceptable toxicity.

Outcomes

Primary Outcome Measures

Relapse-free survival

Secondary Outcome Measures

Safety as assessed by NCI CTCAE version 3.0
Immune response as assessed by HER2 specific T cell immunity and/or intramolecular epitope spreading
Correlation of RFS to the generation of an immune response

Full Information

First Posted
June 20, 2006
Last Updated
February 7, 2020
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00343109
Brief Title
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
Official Title
Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients With Locally Advanced or Stage IV HER2 Positive Breast Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Completed
Study Start Date
March 2004 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This phase II trial is studying how well vaccine therapy works in treating patients receiving trastuzumab for HER2-positive stage IIIB- IV breast cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells
Detailed Description
PRIMARY OBJECTIVES: 1. To estimate the RFS in patients with HER2 positive locally advanced breast cancer vaccinated with a HER2 ICD peptide-based vaccine. SECONDARY OBJECTIVES: To assess the safety of a HER2 ICD peptide-based vaccine administered concurrently with trastuzumab. To determine the immunogenicity of the HER2 ICD peptide based vaccine when given within one year of initiating standard treatment which includes trastuzumab. To determine the incidence of the development of T cell immunity specific for the HER2 ICD. To determine the incidence of the development of intramolecular epitope spreading. To determine the magnitude of the HER2 ICD specific CD4+ and CD8+ immune response generated with immunization. To assess whether there is an association between RFS and the development of an immune response (HER2 specific T cell immunity and/or the development of intramolecular epitope spreading). OUTLINE: Patients receive HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF intradermally (ID) once monthly for 6 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 1, 4, 8, and 12 months and then annually thereafter for up to 5 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HER2-positive Breast Cancer, Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
38 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm I
Arm Type
Experimental
Arm Description
Patients receive HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF intradermally once monthly for 6 months in the absence of disease progression or unacceptable toxicity.
Intervention Type
Biological
Intervention Name(s)
HER-2/neu intracellular domain protein
Other Intervention Name(s)
HER-2 ICD Peptide, HER-2/neu ICD Protein
Intervention Description
Given ID
Intervention Type
Procedure
Intervention Name(s)
leukapheresis
Intervention Description
Optional correlative studies
Intervention Type
Other
Intervention Name(s)
laboratory biomarker analysis
Intervention Description
Correlative studies
Intervention Type
Biological
Intervention Name(s)
sargramostim
Other Intervention Name(s)
GM-CSF, Leukine, Prokine
Intervention Description
Given ID
Intervention Type
Other
Intervention Name(s)
immunologic technique
Other Intervention Name(s)
immunological laboratory methods, laboratory methods, immunological
Intervention Description
Correlative studies
Intervention Type
Biological
Intervention Name(s)
synthetic tumor-associated peptide vaccine therapy
Intervention Description
Given ID
Primary Outcome Measure Information:
Title
Relapse-free survival
Time Frame
At 4 years
Secondary Outcome Measure Information:
Title
Safety as assessed by NCI CTCAE version 3.0
Time Frame
Baseline and 1 month following last vaccination
Title
Immune response as assessed by HER2 specific T cell immunity and/or intramolecular epitope spreading
Time Frame
Baseline, midpoint in the immunization schedule (prior to the 4th vaccine), 1 month after the 6th and last immunization and at 4, 8 and 12 months after the end of vaccinations
Title
Correlation of RFS to the generation of an immune response
Time Frame
Prior to the 4th vaccine, 1 month after the 6th and last immunization and at 4, 8 and 12 months after the end of vaccinations

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Stage IIIB or Stage IIIC breast cancer who are within 1 year of diagnosis and initiating treatment with chemotherapy and trastuzumab; and are in complete remission Stage IV breast cancer in first complete remission and defined as NED (no evidence of disease) or with stable bone only disease who are within 6 months of initiating maintenance trastuzumab NED status should be documented by chest/abdominal CT, PET or PET/CT within the last 90 days Bone only disease documented as stable or healed by PET, PET/CT, or MRI within the last 90 days; stable bone-only disease must be documented with bone scan performed within the last 6 months HER2 overexpression by IHC of 2+ or 3+, in the primary tumor or metastasis or documented gene amplification by FISH analysis; if overexpression is 2+ by IHC, then patients must have HER2 gene amplification documented by FISH Eligible subjects must have been treated to NED or stable bone only disease status with trastuzumab and/or chemotherapy and be off cytotoxic chemotherapy or immunosuppressive agents (e.g. systemic steroids) for at least 30 days prior to enrollment (concurrent hormonal therapy allowed; concurrent bisphosphonate therapy allowed) Patients on trastuzumab should continue trastuzumab monotherapy per standard of care (the dosing and schedule of trastuzumab should follow standard guidelines as described below: trastuzumab 2mg/kg IV weekly or trastuzumab 6mg/kg IV every 3 weeks) Subjects must have an ECOG Performance Status Score =< 1 Non-menopausal female subjects must agree to contraception for the remainder of their childbearing years Male subjects must use an acceptable form of contraception throughout the course of the study Hematocrit >= 30,000 Platelet count >= 100,000 WBC >= 3000/mcl Stable creatinine =< 2.0 mg/dl or a creatinine clearance greater than 60 ml/min Serum bilirubin < 1.5 mg/dl SGOT < 2x ULN Laboratory tests should be performed within 60 days of enrollment Subjects must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment Patients on trastuzumab monotherapy must have adequate cardiac function as demonstrated by normal ejection fraction (EF) on MUGA scan or echocardiogram performed within last 6 months Exclusion Criteria: Subjects cannot be simultaneously enrolled in other treatment studies Patients cannot be receiving any other concurrent immunomodulators besides trastuzumab Any contraindication to receiving GM-CSF based vaccine products Cardiac disease, specifically restrictive cardiomyopathy, unstable angina within the last 6 months prior to enrollment, New York Heart Association functional class III-IV heart failure on active treatment with normalized LVEF on therapy, and symptomatic pericardial effusion Active autoimmune disease Subjects can not have active immunodeficiency disorder, e.g. HIV Cannot be pregnant or breast feeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mary Disis
Organizational Affiliation
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

We'll reach out to this number within 24 hrs